Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

PURPOSE: Carotuximab (DE-122) is a novel endoglin antibody that exhibits potent anti-angiogenic activity. The aim of this study was to evaluate the safety and tolerability of a single intravitreal injection of four ascending doses of carotuximab in patients with persistent exudative age-related macu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez, Victor H., Berger, Brian, Goldberg, Roger, Gordon, Carmelina M., Khurana, Rahul N., Angeles, Raymund, Shams, Naveed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2021
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711001/
https://www.ncbi.nlm.nih.gov/pubmed/34935908
http://dx.doi.org/10.1167/tvst.10.14.27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711001/
https://www.ncbi.nlm.nih.gov/pubmed/34935908
http://dx.doi.org/10.1167/tvst.10.14.27

Ejemplares similares